How immune signaling proteins contribute to giant cell arteritis and polymyalgia rheumatica and what this means for treatment

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are characterized by a hyperproduction of IL-6.

• The role of other circulating cytokines in the pathogenesis of PMR and GCA remains unclear.
• Cytokine mRNA presence in the arterial wall of GCA may distinguish different clinical subgroups of patients.
• The profile of T cell-derived cytokines in GCA suggests that the disease may be driven by a specific immune response (Th1).
• Limited studies have indicated that TNF antagonists could be beneficial in treating patients with refractory PMR and GCA, but this has not been confirmed in larger controlled studies.
• Further research is necessary to clarify the role of circulating cytokines and their potential impact on treatment strategies for PMR and GCA.

Simplified